1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Inflectra To Be First Substitutable Biosimilar In Australia

 
• By Ian Schofield

Australia's Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that Hospira's biosimilar infliximab product Inflectra should be listed on the Pharmaceutical Benefits Scheme. And in a highly controversial move, the PBAC has also said that Inflectra should be "a"-flagged, meaning that it can be substituted by pharmacists for the originator drug, Johnson & Johnson's Remicade.

Australia's Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that Hospira's biosimilar infliximab product Inflectra should be listed on the Pharmaceutical Benefits Scheme. And in a highly controversial move, the PBAC has also said that Inflectra should be "a"-flagged, meaning that it can be substituted by pharmacists for the originator drug, Johnson & Johnson's Remicade.

The PBAC has lost no time in seeking a listing for Inflectra: the product has only just been approved by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 
• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.